Emicizumab activity
- Description
- Emicizumab (Hemlibra) is a bispecific antibody which acts as a coagulation Factor VIII mimetic. Circulating emicizumab is measured using a modified one-stage clotting assay calibrated with emicizumab reference standard. This test is not currently included in the laboratory's scope of UKAS accreditation to ISO15189:2012.
- Clinical details
- Emicizumab has a longer half life in the circulation than convential FVIII replacement therapy. The use of standard coagulation assays for assessing emicizumab is not recommended due to an oversensitivity of its effect on standard assay results.
- Related condition
- Reference range
40 – 60 µg/mL
- Units
- µg/mL
- Synonyms
- Hemlibra, EHL
- Testing site
- Synnovis : Blood Sciences : St Thomas' Hospital
- Laboratory
- Diagnostic Haemostasis and Thrombosis
- Sample type and volume required
- External requests: Citrated platelet poor plasma (500µL x 1 aliquot) or 3.5mL whole blood citrate Internal requests: please refer to EPR label
- Special sample instructions
The sample should be analysed or processed & stored within 4 hours of venepuncture. Please ensure sample tubes are filled exactly to the fill-line as underfilling or overfilling creates a dilution error and leads to inaccurate results.
- Storage and transport
- It is advised that citrated plasma is frozen prior to transport and sent to the laboratory on dry ice to maintain sample quality and integrity. Whole blood can be sent at room temperature, but must be received within 4 hours of venepuncture. Suggest laboratory contacted in advance of sample dispatch.
- Turnaround time
- 7-12 days
- Contacts
Diagnostic Haemostasis and Thrombosis Department
St Thomas’ Hospital
Phone: 020 7188 2797
St Thomas’ Hospital
North Wing – 4th and 5th Floors
Westminster Bridge Road
London SE1 7EHGuy’s Hospital
Phone: 020 7188 7188 ext. 53860
Guy’s Hospital
Southwark Wing – 4th Floor
Great Maze Pond
London SE1 9RT
Outside core hours, contact Duty Haemostasis Biomedical Scientist